Drug Profile
Pertussis immunoglobulin
Latest Information Update: 05 Sep 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pertussis
Most Recent Events
- 19 Aug 1999 New profile
- 19 Aug 1999 Phase-I clinical trials for Pertussis in USA (IV-infusion)